Cagrilintide
Long-acting amylin-receptor analog studied alongside GLP-1 agonists in metabolic research. Prefilled in a ready-to-use 30 mg pen.
The pen ships sealed and pre-dosed. Dial, inject, store refrigerated. No reconstitution, no transfer loss, no volume calculation.
- No reconstitution. Skip bac water, syringes, swirl-and-wait.
- 0.1 mg dose resolution. Mechanical counter, not syringe-barrel guessing.
- Sealed single cartridge. No rubber septum re-entries, no exposed plunger.
- Package-to-dose < 60 s. Pull cap, dial, record. No prep workflow.
- Amylin-receptor agonism (AMY1/2/3 complexes)
- Modulation of gastric emptying, post-prandial glucagon, and central satiety signalling in research models
- Co-administration with Semaglutide (“CagriSema”) — additive body-mass endpoints in Novo Nordisk Phase 2/3 data
- Once-weekly research dosing via albumin-binding design
Areas of laboratory and preclinical research only. Not a description of effects in humans. Research use only — not for human or animal consumption.
- Total mass
- 30 mg
- Volume
- 3 ml
- Concentration
- 10.00 mg / ml
- Format
- Prefilled penReady to use — no reconstitution, no BAC water, no syringe calculation
- Dose increment
- 0.1 mgDial-click precision
- Storage
- 2–8 °C refrigeratedDo not freeze
- Manufacturing
- EU cGMP facilityReleased against pre-registered specs
All products are intended for laboratory research use only. Not for human or animal consumption, diagnostic, or therapeutic use.
Cagrilintide is an acylated amylin analog developed by Novo Nordisk for once-weekly research dosing — most notably co-studied with semaglutide (the 'CagriSema' combination) for additive effects on satiety and body-mass endpoints. A research-context primer on the molecule, the amylin-receptor biology, the CagriSema rationale, and the current Phase 3 program.
Read the primer →Commonly studied with Cagri
Retatrutide
Reta- Dose
- 30 mg
- Purity
- —
- € / mg
- €8.97/mg
Triple GIP/GLP-1/glucagon receptor agonist research peptide — the most-anticipated next-generation metabolic compound, in a Vivaprime prefilled pen.
AOD-9604
AOD- Dose
- 30 mg
- Purity
- —
- € / mg
- €6.63/mg
Modified hGH fragment 176–191 research peptide — widely studied in adipose-tissue and lipolytic-pathway research, in a Vivaprime prefilled pen.
5-Amino-1MQ
- Dose
- 100 mg
- Purity
- —
- € / mg
- €2.29/mg
5-Amino-1MQ small-molecule NNMT-pathway inhibitor research compound — complements NAD+-salvage research. Vivaprime prefilled pen.
Adipotide
- Dose
- 30 mg
- Purity
- —
- € / mg
- €7.97/mg
Experimental pro-apoptotic peptide studied for its selective action on the vasculature supplying white adipose tissue. Prefilled in a ready-to-use pen for research use only.
Quick answers about Cagri
- Is Cagri pre-mixed and ready to use, or do I need to reconstitute it?
- Cagrilintide ships as a sealed prefilled pen. No reconstitution, no bacteriostatic water, no syringe draw. Each pen is pre-dosed with dial-click increments at the factory under EU cGMP release specifications.
- How is Cagri tested and what's on the Certificate of Analysis?
- Every batch is released against a written specification. Identity is confirmed by HPLC-MS plus Amino Acid Analysis; purity is measured by reverse-phase HPLC; residual solvents per ICH Q3C; endotoxin (LAL) per USP. The latest batch and its % purity are published on the product page. Full COA history is available on our lab results page.
- How should Cagri be stored?
- Refrigerate 2–8 °C. Do not freeze. Protect from light. Stable at room temperature up to 28 days once in use.
- How is Cagri shipped?
- Cold-chain shipped from within the EU with ice packs and insulated packaging. Orders ship within 1 business day and most EU addresses arrive in 2–4 business days. Orders over €300 ship free.
- Is Cagri sold for human use?
- No. Cagrilintide is sold strictly for in vitro research and laboratory use by qualified professionals. It is not intended for human consumption, therapeutic, or diagnostic use. This research-use framing is enforced in all product materials and operational documentation.
- How many doses does a 30 mg / 3 ml pen pen of Cagri deliver?
- The exact number of doses depends on the research protocol's per-dose quantity. Pens dial in 0.1 mg increments and total mass per pen is shown on the product page. Divide total mass by your planned per-dose mass to estimate doses.